PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions
- 1 February 2018
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 38 (2), 284-298
- https://doi.org/10.1002/phar.2075
Abstract
Our aim was to summarize published secondary analyses of the PARADIGM-HF trial. In the original trial, published in September 2014, sacubitril/valsartan significantly reduced the primary composite outcome of cardiovascular death or heart failure hospitalization compared to enalapril. This summary provides a resource for clinicians to review subsequent analyses of the landmark trial evaluating the benefit of sacubitril/valsartan in various subgroups and providing information regarding optimal use of this new therapy in the broader heart failure population. A full list of publications of the existing PARDADIGM-HF post hoc analyses was obtained and summarized, grouped by focus (e.g., severity of illness, tolerability). Twenty-six publications and one abstract analyzing the PARADIGM-HF trial were reviewed, summarizing the most important results that compared the benefits of sacubitril/valsartan to enalapril, including pertinent subgroup information from each analysis. Key publications evaluated the treatment effect of sacubitril/valsartan based on heart failure severity (i.e., ejection fraction or heart failure risk scores), impact on alternate outcomes, influence of additional therapies, tolerability in patients with comorbidities (i.e., diabetes), long-term benefits, and cost-effectiveness. In addition, nine ongoing phase III and phase IV clinical trials with sacubitril/valsartan were briefly summarized to address potential future uses in more extensive heart failure settings. The benefit of sacubitril/valsartan over enalapril for the primary endpoint in the PARADIGM-HF trial is maintained throughout numerous secondary analyses. Though the subgroups analyzed are based on participants from a single clinical trial, clinicians can more confidently incorporate this novel therapy into practice with expanded knowledge of these existing analyses as well as ongoing prospective trials.Keywords
This publication has 49 references indexed in Scilit:
- Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow ReserveCirculation, 2013
- The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialEuropean Heart Journal, 2013
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of the American College of Cardiology, 2013
- Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic DysfunctionJournal of the American College of Cardiology, 2012
- The Value of Atorvastatin Over the Product Life Cycle in the United StatesClinical Therapeutics, 2011
- Changing Characteristics and Mode of Death Associated With Chronic Heart Failure Caused by Left Ventricular Systolic DysfunctionCirculation: Heart Failure, 2011
- Divergent Trends in Survival and Readmission Following a Hospitalization for Heart Failure in the Veterans Affairs Health Care System 2002 to 2006Journal of the American College of Cardiology, 2010
- Interpreting the Results of Cost-Effectiveness StudiesJournal of the American College of Cardiology, 2008
- Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)The American Journal of Cardiology, 2008
- Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure PatientsCirculation, 2005